Last updated: October 6, 2026
SITAVIG is a prescription 50 mg acyclovir mucoadhesive buccal tablet for treating recurrent herpes labialis, or cold sores. Its commercial proposition is based on single-dose administration and adhesion to the gum, rather than superior antiviral activity. The product competes with low-cost generic oral acyclovir, valacyclovir and topical cold-sore treatments.
SITAVIG has a defensible delivery technology but a limited market ceiling. Its financial trajectory is likely to reflect niche branded-drug economics: modest volume, premium pricing, dependence on prescriber and patient convenience, and vulnerability to generic substitution and channel restrictions. Public filings do not provide a reliable standalone revenue series for SITAVIG, so product-level sales and profitability cannot be quantified from public sources.
What is SITAVIG and how does it work?
SITAVIG contains acyclovir, an established antiviral agent active against herpes simplex virus. The tablet is placed on the upper gum at the onset of a recurrent herpes labialis episode. It adheres to the buccal mucosa and releases acyclovir locally.
The FDA-approved US product is a 50 mg buccal tablet indicated for recurrent herpes labialis in immunocompetent adults. The treatment is administered as a single dose at the earliest sign of symptoms, which differentiates it from multi-dose oral acyclovir regimens. The US application is NDA 202276. (U.S. Food and Drug Administration [FDA], 2013)
SITAVIG product profile
| Attribute |
SITAVIG profile |
| Active ingredient |
Acyclovir |
| Strength |
50 mg |
| Dosage form |
Mucoadhesive buccal tablet |
| Primary indication |
Recurrent herpes labialis |
| Administration |
Single tablet applied to the upper gum |
| Regulatory route |
FDA 505(b)(2) NDA |
| Main clinical differentiation |
Single-dose local delivery and convenience |
| Principal alternatives |
Generic oral acyclovir, valacyclovir, topical antivirals |
| Commercial category |
Niche branded prescription antiviral |
The formulation does not create a new antiviral mechanism. Its value rests on drug delivery, adherence and convenience.
What is the market size for SITAVIG?
The addressable disease population is large, but the branded prescription segment is narrower. Herpes labialis is common and recurrent, yet many patients self-treat with over-the-counter products or do not seek treatment. Generic oral antivirals also limit the premium available for a branded formulation.
SITAVIG’s practical market is determined by five factors:
- Patients who recognize symptoms early enough to benefit from treatment.
- Patients who consult a physician or obtain a prescription.
- Physicians willing to prescribe a branded buccal formulation.
- Payers willing to reimburse the product.
- Pharmacies able to source and dispense it.
The product therefore addresses a large clinical condition but a limited reimbursed market. Its commercial opportunity is closer to a specialty convenience product than to a mass-market antiviral.
Key market drivers
- Single-dose use can improve adherence compared with five-times-daily oral acyclovir.
- Patients with frequent cold sores may value rapid, convenient treatment.
- Physicians may prescribe SITAVIG where treatment initiation is delayed by concerns about dosing complexity.
- Specialty pharmacies and telehealth channels can support prescription access.
- Awareness of early antiviral treatment can increase demand.
Key market restraints
- Acyclovir and valacyclovir are available in inexpensive generic forms.
- Many consumers use OTC docosanol or other topical products.
- Recurrent cold sores are often self-limited.
- The product must be applied correctly to the gum.
- Insurance formularies can place branded products behind generic antivirals.
- A single-use product has limited opportunities for repeat prescription expansion beyond recurrence frequency.
How does SITAVIG compare with generic acyclovir and valacyclovir?
SITAVIG’s primary advantage is administration, not antiviral potency. Generic oral acyclovir and valacyclovir have broad physician familiarity, established reimbursement and low acquisition cost.
| Product |
Administration |
Dose burden |
Main commercial advantage |
Main weakness versus SITAVIG |
| SITAVIG |
Single buccal tablet |
One application |
Convenience and localized delivery |
Higher branded-product cost |
| Generic acyclovir |
Oral tablets or capsules |
Multiple daily doses |
Low price and familiarity |
Greater dosing burden |
| Valacyclovir |
Oral tablets |
Fewer doses than acyclovir |
Strong physician adoption and generic availability |
Still requires oral dosing |
| Docosanol |
Topical OTC |
Repeated application |
Direct consumer access |
Less convenient and nonprescription positioning |
Valacyclovir is the strongest commercial substitute when physicians prioritize fewer oral doses. SITAVIG is more differentiated against multi-dose acyclovir than against valacyclovir.
What patents protect SITAVIG?
SITAVIG’s intellectual-property value is linked primarily to its mucoadhesive buccal delivery system, manufacturing process and formulation design. The active ingredient, acyclovir, is an old generic compound and does not provide meaningful composition-of-matter exclusivity.
Likely patent value by category
| IP category |
Strategic value |
Exposure |
| Acyclovir compound patent |
None or immaterial |
Compound is long off patent |
| Buccal delivery formulation |
High relative value |
Vulnerable to design-around |
| Mucoadhesive composition |
High relative value |
Requires technical non-infringement strategy |
| Manufacturing process |
Moderate |
May be difficult to detect in finished product |
| Method of use |
Moderate to low |
Narrow indication and obvious generic alternatives |
| Trademark and brand |
Commercial value |
Does not block generic acyclovir |
The relevant patent estate is narrower than the patent estate for a new molecular entity. Its strength depends on whether claims cover the specific combination of acyclovir loading, mucoadhesion, release characteristics and placement method.
What is the Orange Book status of SITAVIG?
SITAVIG was approved under an FDA NDA rather than an ANDA. FDA labeling confirms the product’s prescription status and indication. The commercial importance of any Orange Book listing depends on whether unexpired patents covering the product remain listed and whether a future ANDA applicant files a Paragraph IV certification.
The principal regulatory risk is not loss of active-ingredient exclusivity. A generic entrant could seek approval by demonstrating pharmaceutical equivalence and bioequivalence, while challenging or designing around formulation patents.
A current Orange Book patent-expiration assessment requires a live review of the FDA listing and applicable patent records. Product-level patent expiration dates should not be treated as established solely from the approval date.
When does SITAVIG lose exclusivity?
SITAVIG has already lost any practical new-chemical-entity exclusivity associated with acyclovir because acyclovir was approved decades before SITAVIG. The commercial protection comes from formulation patents, regulatory exclusivity attached to the NDA, trademarks and market execution.
The relevant exclusivity layers are:
| Exclusivity layer |
SITAVIG position |
| New chemical entity |
Not applicable |
| Orphan-drug exclusivity |
Not applicable to recurrent herpes labialis |
| Pediatric exclusivity |
No material public basis identified |
| New clinical investigation exclusivity |
Potentially relevant only if specifically granted |
| Formulation patents |
Potentially material |
| Method-of-use patents |
Potentially material but narrow |
| Trademark protection |
Ongoing if maintained |
| Regulatory approval |
Does not prevent all acyclovir competition |
A generic applicant could challenge listed patents through Paragraph IV certification or wait for patent expiry. Because the clinical indication is common and the molecule is generic, generic entry risk is structurally higher than for a patented antiviral molecule.
Which companies are challenging SITAVIG?
No major public Paragraph IV litigation campaign involving SITAVIG is established in the core public FDA materials cited here. That does not eliminate the possibility of confidential patent challenges, unreported commercial disputes or future ANDA activity.
The likely competitive threat comes from generic acyclovir and valacyclovir manufacturers rather than from a direct copy of the buccal tablet. A generic company may prefer to compete with an oral formulation because the regulatory pathway, manufacturing process and market access are simpler.
What is the FDA regulatory status of SITAVIG?
SITAVIG received FDA approval for recurrent herpes labialis in immunocompetent adults. The product’s regulatory profile supports continued commercialization as an approved prescription drug, provided the NDA remains active and the sponsor maintains required manufacturing, labeling and pharmacovigilance obligations. (FDA, 2013)
The product’s regulatory advantages include:
- An established indication.
- A defined single-dose regimen.
- A full FDA-approved label.
- Clinical data supporting efficacy and safety for the approved use.
The principal regulatory limitations are equally important. The label does not convert SITAVIG into a broad treatment for herpes infections, shingles or immunocompromised patients. Expansion into new indications would require additional clinical and regulatory investment.
What is SITAVIG’s financial trajectory?
Public information does not support a verified standalone revenue or EBITDA history for SITAVIG. The product has been associated with corporate and commercial partners over time, but reported company results generally do not isolate SITAVIG revenue with enough detail for a reliable time series.
The economically defensible trajectory is:
Launch phase
Commercial performance depended on educating prescribers about a new dosage form for a familiar generic molecule. Launch costs likely included physician promotion, pharmacy distribution, payer access and patient awareness.
Early commercial phase
The product could command a premium where convenience justified the price. Volume growth was constrained by generic oral alternatives and the episodic nature of cold sores.
Mature niche phase
The economic model shifts toward retention of repeat users, targeted prescriber promotion and disciplined distribution. Revenue growth depends more on price, reimbursement and patient persistence than on expansion of the underlying disease population.
Long-term phase
The product faces declining economic protection when formulation patents expire, when payer coverage weakens or when a generic buccal competitor enters. Generic oral antivirals remain a continuing substitute even without a direct SITAVIG generic.
What revenue exposure does SITAVIG create for its owner?
SITAVIG is unlikely to represent material revenue exposure for a diversified pharmaceutical company unless the product is unusually concentrated within a small commercial portfolio. Its strategic value is more likely to come from:
- Royalty or licensing income.
- A niche branded-product contribution.
- Use of a drug-delivery platform.
- Commercial access to dermatology, primary-care or telehealth prescribers.
- A platform for other mucoadhesive products.
Revenue quality is mixed. Repeat use can support recurring demand because herpes labialis recurs, but each episode produces a limited number of units. The product does not generate chronic daily use, which caps annual prescription volume per patient.
How strong is the SITAVIG patent estate?
SITAVIG has moderate formulation-based protection and weak molecule-based protection.
Patent strength is highest if claims cover a narrow but commercially essential combination that competitors cannot easily reproduce. Strength is lower if the claims cover broad concepts such as oral mucosal adhesion or known acyclovir delivery techniques.
The estate is most exposed to:
- Design-around formulations.
- Generic oral substitution.
- Challenges to validity or claim construction.
- Difficulty proving infringement of process claims.
- Limited damages if the branded market remains small.
SITAVIG is therefore a defensible niche product, not a high-barrier pharmaceutical franchise comparable to a protected biologic or novel small molecule.
What generic launch scenarios exist for SITAVIG?
Scenario 1: Oral generic substitution continues
This is the baseline risk. Generic acyclovir and valacyclovir continue to capture patients without a direct SITAVIG copy. The product retains a convenience segment but experiences pricing pressure.
Scenario 2: Direct buccal generic launch
A direct competitor could erode price and volume more quickly. The entrant would need to address formulation equivalence, bioequivalence and any listed patents.
Scenario 3: Patent challenge followed by settlement
A Paragraph IV dispute could lead to a settlement with an agreed generic entry date. The financial impact would depend on the entry date, royalty terms and whether the generic receives an authorized launch pathway.
Scenario 4: Brand repositioning
The owner could protect revenue through specialty pharmacy, telehealth, patient support or targeted payer contracting. This would preserve a convenience premium but would not remove generic substitution risk.
What licensing deals and commercial partnerships affect SITAVIG?
SITAVIG’s commercial history has involved licensing and commercialization arrangements connected to the product’s developer and US commercial rights. Public corporate disclosures have not provided a consistent, current, standalone accounting of sales, royalties or partner economics. Corporate ownership and commercialization arrangements should therefore be separated from the product’s FDA approval status.
For valuation purposes, the important contract terms are:
- Territory.
- Upfront consideration.
- Milestones.
- Net-sales royalties.
- Minimum commercial obligations.
- Manufacturing responsibility.
- Rights to sublicense.
- Reversion triggers.
Without verified current agreement terms, licensing value cannot be quantified.
How does SITAVIG compare with competing antiviral franchises?
| Criterion |
SITAVIG |
Generic acyclovir |
Valacyclovir |
| Molecular differentiation |
None |
None |
Prodrug advantage |
| Delivery differentiation |
Stronger |
Weak |
Moderate |
| Price position |
Premium branded |
Low-cost generic |
Generic or branded |
| Adherence proposition |
Single application |
Multiple doses |
Reduced oral dosing |
| Patent strength |
Formulation-dependent |
Minimal |
Mature generic competition |
| Reimbursement risk |
High |
Low |
Moderate |
| Market scale |
Niche |
Broad |
Broad |
| Generic-entry risk |
High over time |
Already generic |
Already generic |
Key Takeaways
- SITAVIG is a 50 mg acyclovir mucoadhesive buccal tablet for recurrent herpes labialis.
- Its commercial differentiation is single-dose administration, not a new antiviral mechanism.
- Generic acyclovir and valacyclovir impose persistent price and formulary pressure.
- The relevant IP is formulation-based, while acyclovir itself has no meaningful remaining composition-of-matter protection.
- SITAVIG’s FDA approval supports continued prescription commercialization, but it does not prevent substitution with oral generic antivirals.
- No reliable public standalone revenue series supports precise sales or profitability estimates.
- The product’s financial trajectory is most consistent with a mature, targeted branded niche.
- The largest risks are payer exclusion, generic oral substitution, formulation patent expiry and direct buccal competition.
- The strongest commercial opportunity is a convenience-focused segment supported by telehealth, specialty pharmacy and repeat cold-sore patients.
FAQs
Is SITAVIG stronger than oral acyclovir?
SITAVIG is not a stronger antiviral on a molecular basis. Its advantage is the single-dose buccal delivery system and convenience.
Can a generic company copy SITAVIG?
A generic company could pursue a direct buccal equivalent or compete indirectly with oral acyclovir and valacyclovir. The pathway depends on formulation equivalence, FDA requirements and any unexpired listed patents.
Is SITAVIG an OTC product?
No. SITAVIG is an FDA-approved prescription product for recurrent herpes labialis.
Does SITAVIG have biologic or biosimilar risk?
No. SITAVIG contains the small-molecule antiviral acyclovir. Biosimilar regulation does not apply. Its main competitive risks are generic drugs and alternative formulations.
Is SITAVIG commercially attractive for licensing?
It can be attractive as a focused branded product or drug-delivery asset, but valuation depends on current net sales, payer coverage, patent life, manufacturing cost and partner economics. Public sources do not establish a current standalone valuation.
References
-
U.S. Food and Drug Administration. (2013). SITAVIG (acyclovir) buccal tablet prescribing information. FDA.
-
U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs. FDA.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book. FDA.
-
National Library of Medicine. (2024). DailyMed: Acyclovir and SITAVIG prescribing information. U.S. National Library of Medicine.
